J
Jaime Blais
Researcher at Janssen Pharmaceutica
Publications - 4
Citations - 46
Jaime Blais is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Canagliflozin & Kidney disease. The author has an hindex of 2, co-authored 4 publications receiving 11 citations.
Papers
More filters
Journal ArticleDOI
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Brendon L. Neuen,Toshiaki Ohkuma,Bruce Neal,David R. Matthews,Dick de Zeeuw,Kenneth W. Mahaffey,Greg Fulcher,Jaime Blais,Qiang Li,Meg Jardine,Meg Jardine,Vlado Perkovic,Vlado Perkovic,David C. Wheeler,David C. Wheeler +14 more
TL;DR: The KDIGO classification system may be able to identify individuals who might derive greater benefits for end-organ protection from treatment with canagliflozin, and absolute risk reductions are likely greater for individuals at higher KDigO risk.
Journal ArticleDOI
Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy
Michael Durkin,Jaime Blais +1 more
TL;DR: In this article, the authors used clinical trial data from the CREDENCE trial to estimate the difference in time to dialysis by treatment arm and estimated the economic value of that delay.
Journal ArticleDOI
Real-World Diagnosis and Treatment of Diabetic Kidney Disease
Fatima Rodriguez,Donghyun Lee,Sanchit Gad,Matheus P Santos,Robert Beetel,Joseph Vasey,Robert A. Bailey,Aarti A Patel,Jaime Blais,Matthew R. Weir,Rajesh Dash +10 more
TL;DR: In this article, a real-world analysis of patients with Type 2 diabetes mellitus (T2DM) and diabetic kidney disease (DKD) was performed to detect onset of DKD and determine methods and timing of diagnosis and time to initiation of ACEi/ARB therapy.
Journal ArticleDOI
Effects of canagliflozin on cardiovascular death and hospitalization for heart failure by baseline estimated glomerular filtration rate: integrated analyses from the CANVAS Program and CREDENCE
Kenneth W. Mahaffey,George L. Bakris,Jaime Blais,Christopher P. Cannon,David Z.I. Cherney,C V Damaraju,Jagadish Gogate,Tom Greene,H J L Heerspink,James L. Januzzi,Mikhail Kosiborod,Adeera Levin,Ildiko Lingvay,Matthew R. Weir,Perkovic +14 more
TL;DR: CANA significantly reduced the risk of CV death or HHF, jointly and individually, in participants with T2DM and high CV risk or CKD in the CANVAS Program and the CREDENCE trial, with consistent benefits observed regardless of baseline eGFR.